aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

Rhea-AI Summary

aTyr Pharma, Inc. (Nasdaq: LIFE) announced it will report its second quarter 2020 financial results and provide a corporate update on August 13, 2020, after market close. The company focuses on developing innovative medicines targeting novel immunological pathways, with its lead product ATYR1923 aimed at treating inflammatory lung diseases by binding to the neuropilin-2 receptor. The conference call is scheduled for the same day at 5:00 p.m. EDT.

Positive

• Focus on innovative immunological pathways with a potential pipeline derived from 20 tRNA synthetase genes.
• Lead candidate ATYR1923 targets the neuropilin-2 receptor for inflammatory lung diseases.

Negative

• None.

SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2020 financial results and provide a corporate update after the market close on Thursday, August 13, 2020.

Conference Call and Webcast Details:
Thursday, August 13th @ 5:00 p.m. EDT / 2:00 p.m. PDT
Domestic:  844-358-9116
International:  209-905-5951
Conference ID:  5176802
Webcast: http://investors.atyrpharma.com/events-and-webcasts

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. 

Contact:

Ashlee Dunston

Investor Relations, aTyr Pharma

adunston@atyrpharma.com

FAQ

When will aTyr Pharma report its second quarter 2020 financial results?

aTyr Pharma will report its second quarter 2020 financial results on August 13, 2020, after market close.

What is the focus of aTyr Pharma's research and development?

aTyr Pharma focuses on discovering and developing innovative medicines based on novel immunological pathways.

What is the primary product candidate of aTyr Pharma?

The primary product candidate of aTyr Pharma is ATYR1923, designed to treat inflammatory lung diseases.

What time is aTyr Pharma's conference call on August 13, 2020?

The conference call is scheduled for August 13, 2020, at 5:00 p.m. EDT.

What is aTyr Pharma's stock symbol?

aTyr Pharma's stock symbol is LIFE.